Loading...
XSHE002219
Market cap1.15bUSD
Jan 14, Last price  
2.58CNY
1D
4.03%
1Q
0.00%
Jan 2017
-78.46%
IPO
30.61%
Name

New Journey Health Technology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002219 chart
P/E
273.93
P/S
2.35
EPS
0.01
Div Yield, %
1.23%
Shrs. gr., 5y
12.64%
Rev. gr., 5y
-1.33%
Revenues
3.59b
+13.88%
83,973,043100,225,011130,103,412198,231,917284,972,508285,116,048299,331,669307,244,763336,964,448564,725,360685,657,6501,181,728,2232,175,221,1873,399,324,1433,838,392,1973,684,467,7212,805,895,4943,016,070,7333,152,734,8803,590,482,060
Net income
31m
-80.29%
13,729,38717,578,34219,257,95433,796,74544,511,22547,805,40765,961,42971,345,72673,672,375169,827,048257,332,861323,626,317403,631,489202,809,2630000156,121,50230,776,551
CFO
291m
+8.56%
76,41436,535,83013,549,75231,880,72122,369,35632,627,52664,425,81594,803,99382,705,472158,400,972193,353,694219,021,90300522,565,203549,512,401283,796,318277,294,763268,039,414290,977,690
Dividend
Feb 28, 20140.1 CNY/sh
Earnings
May 09, 2025

Profile

Hengkang Medical Group Co.,Ltd provides medical services, pharmaceuticals, health care, and daily chemical products in China and internationally. It operates approximately 11 hospitals. The company also manufactures pharmaceutical products in the areas of analgesia, cold, cough, gynecology, cardiovascular, digestive, and urinary systems. In addition, it offers Chinese herbal medicines, infusion, and hemostasis products, as well as daily chemical products. The company was formerly known as Gansu Duyiwei Biological Pharmaceutical Co., Ltd. and changed its name to Hengkang Medical Group Co.,Ltd in January 2014. Hengkang Medical Group Co.,Ltd. was founded in 2001 and is based in Chengdu, China.
URL
http://www.njhtg.com/
IPO date
Mar 06, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,590,482
13.88%
3,152,735
4.53%
Cost of revenue
3,187,901
2,533,392
Unusual Expense (Income)
NOPBT
402,581
619,343
NOPBT Margin
11.21%
19.64%
Operating Taxes
(28,655)
23,183
Tax Rate
3.74%
NOPAT
431,236
596,160
Net income
30,777
-80.29%
156,122
 
Dividends
(103,987)
Dividend yield
1.01%
Proceeds from repurchase of equity
(19,514)
BB yield
0.19%
Debt
Debt current
716,486
1,127,679
Long-term debt
962,885
501,865
Deferred revenue
2,877
2,105
Other long-term liabilities
95,898
49,362
Net debt
1,092,267
1,064,735
Cash flow
Cash from operating activities
290,978
268,039
CAPEX
(195,170)
Cash from investing activities
(335,383)
Cash from financing activities
62,821
FCF
100,907
833,985
Balance
Cash
580,235
558,913
Long term investments
6,870
5,897
Excess cash
407,581
407,173
Stockholders' equity
387,563
3,435,862
Invested Capital
3,456,270
2,933,429
ROIC
13.50%
23.33%
ROCE
10.39%
18.29%
EV
Common stock shares outstanding
3,382,039
3,264,164
Price
3.03
-23.10%
3.94
7.65%
Market cap
10,247,577
-20.32%
12,860,805
88.39%
EV
11,378,661
13,967,783
EBITDA
619,779
785,864
EV/EBITDA
18.36
17.77
Interest
123,533
142,584
Interest/NOPBT
30.69%
23.02%